Full Version of the May 2013 Issue

Publication
Article
Targeted Therapies in OncologyMay 2013
Volume 2
Issue 3

Full version of the May 2013 Targeted Therapy News

View the full PDF

Targeted Therapy Newscovers the most important developments in cancer care today, personalized medicine and targeted therapies. The publication is strongly committed to providing oncology healthcare professionals the information and resources they need to deliver the best possible treatment to their patients

This issue features articles on:

  • Key targeted trials being presented at ASCO
  • Nongenetic mechanisms of cancer cell diversity and treatment response
  • Platinum resistance in ovarian cancer
  • HER2-targeted agents in NSCLC

Open publication- Freepublishing-More cancer

Articles in this issue
Bundled Payment: Practice Savior or Killer?
Bundled Payment: Practice Savior or Killer?
Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate Cancer
Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate Cancer
Notch Holds Promise, but Presents Obstacles as Cancer Target
Notch Holds Promise, but Presents Obstacles as Cancer Target
Trials Examine Use of T-DM1 as Combination Therapy for HER2 Breast Cancer
Trials Examine Use of T-DM1 as Combination Therapy for HER2 Breast Cancer
Spotlight on Novel Agents in Early Development
Spotlight on Novel Agents in Early Development
Treating Elderly Patients With CLL
Treating Elderly Patients With CLL
Biomarkers Still Needed in Prostate Cancer
Biomarkers Still Needed in Prostate Cancer
New Developments in Oral Targeted Agents for Advanced Colorectal Cancer
New Developments in Oral Targeted Agents for Advanced Colorectal Cancer
Researchers Identify How Nongenetic Mechanisms of Cancer Cell Diversity Can Affect Treatment Response
Researchers Identify How Nongenetic Mechanisms of Cancer Cell Diversity Can Affect Treatment Response
Numerous Drug Classes Studied for Use in Follicular and Other Lymphomas
Numerous Drug Classes Studied for Use in Follicular and Other Lymphomas
A Guide to ASCO 2013: Key Targeted Trials
A Guide to ASCO 2013: Key Targeted Trials
Full Version of the May 2013 Issue
Full Version of the May 2013 Issue

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer

Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer

Chris Ryan
May 15th 2025
Article

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.

Read More

Dostarlimab Shows Response in Endometrial Cancer

Dostarlimab Shows Response in Endometrial Cancer

Ashling Wahner
May 14th 2025
Article

Read More

Seiter Explores Time of Initiation and Alternate Dosing of Ruxolitinib in Myelofibrosis

Seiter Explores Time of Initiation and Alternate Dosing of Ruxolitinib in Myelofibrosis

Targeted Oncology Staff
May 14th 2025
Article

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use of ruxolitinib to treat myelofibrosis.

Read More

Atezolizumab/Ipatasertib Demonstrates Potential in Solid Tumors

Atezolizumab/Ipatasertib Demonstrates Potential in Solid Tumors

Morgan Bayer
May 14th 2025
Article

Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies Congress 2025.

Read More

Frontline Dato-DXd Looks Promising in NSCLC

Frontline Dato-DXd Looks Promising in NSCLC

Morgan Bayer
May 13th 2025
Article

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Read More

T-DXd’s Robust Efficacy and Response Continue in Frontline MBC

T-DXd’s Robust Efficacy and Response Continue in Frontline MBC

Tony Berberabe, MPH
May 13th 2025
Article

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

Read More